Arkolith/Insider Trading/SPRO/Form 4

Keutzer Timothy

Chief Operating OfficerSpero Therapeutics, Inc. (SPRO) · full profile →Form 4 · filed Feb 5, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$44K
Net Open-Market Flow
-$44K
Transactions
4
4 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 5, 2025Sell(S)25K$0.78$19K741K
Feb 5, 2025Sell(S)28K$0.78$22K766K
Feb 5, 2025Sell(S)4K$0.78$3K794K
Feb 3, 2025Grant(A)266K—$0798K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-014866) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML